ProCE Banner Activity

Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS

Slideset Download
Conference Coverage

Low-dose lenalidomide prolonged time to transfusion dependency compared with placebo in patients with low-risk MDS and del(5q).

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen